학술논문
1370P - Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Document Type
Abstract
Author
Source
In Annals of Oncology October 2019 30 Supplement 5:v559-v559
Subject
Language
ISSN
0923-7534